FluoretiQ Diagnostic Device

Accelerating the Fight Against Antibiotic Resistance

Project Description

FluoretiQ partnered with Sanner to take its laboratory prototype one step closer to becoming a diagnostic product.

The Challenge

Antibiotic resistance is a growing global healthcare challenge, with up to one in two antibiotics being misused. Every instance of inappropriate antibiotic use contributes to the growing problem, making it increasingly important to ensure patients receive the right treatment first time.

A key part of addressing this challenge is improving the speed and accuracy of diagnosis, enabling healthcare professionals to make informed treatment decisions and avoid unnecessary or ineffective antibiotic prescriptions.

The Solution

FluoretiQ is developing innovative technology that enables the rapid identification of bacterial infections in urine.

By providing faster identification of infections, the technology aims to help clinicians select the most appropriate treatment sooner, reducing delays and improving the likelihood of effective treatment from the outset.

The Project

With support from Sanner, FluoretiQ is working to take its laboratory prototype one step closer to becoming a diagnostic product.

This project represents an important stage in the development journey, helping to bridge the gap between an innovative laboratory concept and a product with the potential to make a real difference in healthcare.

The Impact

The potential benefits extend beyond individual patient care. By enabling more targeted antibiotic treatment, FluoretiQ’s technology could:

  • Improve patient outcomes through faster identification of bacterial infections and more effective treatment.
  • Reduce unnecessary antibiotic use by helping clinicians make better-informed prescribing decisions.
  • Lower healthcare costs by reducing ineffective treatments and associated delays.
  • Help tackle antibiotic resistance by supporting more responsible use of existing antibiotics.

Looking Ahead

By bringing faster, more accurate infection diagnosis closer to clinical application, FluoretiQ is taking an important step towards addressing one of healthcare’s most pressing challenges.

Through its project with Sanner, the company is moving closer to delivering a diagnostic solution that could benefit patients, healthcare providers and the wider fight against antibiotic resistance.

Get in touch with our team today